CAS Number: 50-35-1
Molecular Weight: 258.2295
Method of Analysis: USP 41
erythema nodosum leprosum (ENL)
In patients with erythema nodosum leprosum (ENL) the mechanism of action is not fully understood. Available data from in vitro studies and preliminary clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor-alpha (TNF-a) production and down-modulation of selected cell surface adhesion molecules involved in leukocyte migration. For example, administration of thalidomide has been reported to decrease circulating levels of TNF-a in patients with ENL, however, it has also been shown to increase plasma TNF-a levels in HIV-seropositive patients. As a cancer treatment, the drug may act as a VEGF inhibitor.
Preserve in tight containers.Protected from light,and Store at controlled room temperature.
The final product is packed in polyethylene nylon plastic bag and then packaged in a 3-layered aluminum foil.